In this paper, we present the outline of the ADAPT ALEC trial: a prospective, multicenter, phase IV, RCT to study the clinical benefit of TDM in patients with advanced ALK+ NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.